By contrast, the analysis of the multicenter Cancer of Pancreas Screening (CAPS5) study, which included 269 BRCA2 P/LPV carriers and 68 BRCA1 P/LPV carriers with a median follow-up of 4 years, found that 77.8% of the PDACs diagnosed within the high-risk cohort (screened by annual EUS and/or MRI/MRCP, with modified surveillance interval in case of radiologically suspicious lesion) had stage I disease and 5-year survival of 73.3%. The gene discussed is BRCA2; the disease is cancer.